Revenue
$16.61B
Fiscal year ended 2026-06-30Operating income
Unavailable
Fiscal year ended 2026-06-30Free cash flow
$4.48B
Fiscal year ended 2026-06-30Merck & Co., Inc. (MRK) reported revenue of $16.61B and net income of -$1.34B for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Merck & Co., Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $16.61B | $16.29B | $16.40B | $17.28B | $15.81B | $15.53B | $15.62B | $16.66B | $16.11B | $15.78B |
| Cost of revenue | $4.40B | $4.20B | $5.55B | $3.86B | $3.56B | $3.42B | $3.83B | $4.08B | $3.74B | $3.54B |
| Gross profit | $12.21B | $12.09B | $10.85B | $13.42B | $12.25B | $12.11B | $11.80B | $12.58B | $12.37B | $12.24B |
| Operating income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Net income | -$1.34B | -$4.24B | $2.96B | $5.78B | $4.43B | $5.08B | $3.74B | $3.16B | $5.46B | $4.76B |
| Research & development | $9.74B | $12.59B | $3.89B | $4.23B | $4.05B | $3.62B | $4.58B | $5.86B | $3.50B | $3.99B |
| Weighted-average diluted shares | shares 2.47B | shares 2.47B | Unavailable | shares 2.50B | shares 2.51B | shares 2.53B | Unavailable | shares 2.54B | shares 2.54B | shares 2.54B |
| Pretax income | -$683.00M | -$3.53B | $3.42B | $6.74B | $5.00B | $5.90B | $4.17B | $4.09B | $6.01B | $5.67B |
| Income tax expense | $654.00M | $709.00M | $458.00M | $958.00M | $571.00M | $818.00M | $426.00M | $929.00M | $545.00M | $903.00M |
| Diluted EPS | $-0.54 | $-1.72 | Unavailable | $2.32 | $1.76 | $2.01 | Unavailable | $1.24 | $2.14 | $1.87 |
| Selling, general & administrative | $2.90B | $2.70B | $2.90B | $2.63B | $2.65B | $2.55B | $2.86B | $2.73B | $2.74B | $2.48B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6.85B | $5.33B | $14.56B | $18.17B | $8.01B | $8.63B | $13.24B | $14.59B | $11.30B | $5.58B |
| Total assets | $129.80B | $128.68B | $136.87B | $129.55B | $117.52B | $115.12B | $117.11B | $117.53B | $112.63B | $105.85B |
| Current assets | $36.68B | $35.02B | $43.52B | $47.56B | $37.06B | $35.50B | $38.78B | $40.36B | $38.20B | $31.44B |
| Total liabilities | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Current liabilities | $27.73B | $26.94B | $28.33B | $28.63B | $26.04B | $25.17B | $28.42B | $29.59B | $26.06B | $25.10B |
| Total equity incl. NCI | $41.98B | $45.93B | $52.66B | $51.91B | $49.06B | $48.40B | $46.37B | $44.56B | $43.65B | $40.42B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $6.21B | $6.48B | $6.66B | $6.44B | $6.60B | $6.20B | $6.11B | $6.24B | $6.47B | $6.51B |
| Accounts receivable | $12.56B | $12.21B | $11.78B | $12.12B | $11.85B | $10.79B | $10.28B | $11.38B | $11.64B | $11.37B |
| Goodwill | $21.58B | $21.58B | $21.58B | $21.59B | $21.59B | $21.68B | $21.67B | $21.70B | $21.16B | $21.18B |
| Long-term debt | $51.08B | $46.67B | $46.75B | $39.97B | $33.97B | $33.48B | $34.46B | $34.98B | $34.72B | $31.14B |
| Accounts payable | $3.83B | $3.86B | $4.40B | $4.15B | $3.89B | $3.78B | $4.08B | $3.59B | $3.52B | $3.51B |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.37B | $3.92B | $2.86B | $7.82B | $3.29B | $2.50B | $3.45B | $9.29B | $5.64B | $3.09B |
| Capital expenditures | $893.00M | $991.00M | $1.03B | $987.00M | $764.00M | $1.33B | $937.00M | $783.00M | $791.00M | $861.00M |
| Investing cash flow | -$5.60B | -$10.21B | -$11.20B | -$283.00M | -$770.00M | -$1.49B | -$1.44B | -$3.84B | -$1.07B | -$1.38B |
| Financing cash flow | $1.76B | -$2.98B | $4.75B | $2.64B | -$3.56B | -$5.76B | -$3.01B | -$2.42B | $1.22B | -$2.81B |
| Net change in cash | $1.49B | -$9.29B | -$3.57B | $10.19B | -$659.00M | -$4.59B | -$1.37B | $3.32B | $5.70B | -$1.24B |
| Stock-based compensation | $298.00M | $185.00M | $205.00M | $204.00M | $216.00M | $195.00M | $187.00M | $195.00M | $203.00M | $176.00M |
| Common dividends paid | $2.14B | $2.10B | $2.02B | $2.03B | $2.08B | $2.05B | $1.95B | $1.95B | $1.99B | $1.95B |
| Common share repurchases | $757.00M | $874.00M | $1.25B | $1.32B | $1.34B | $1.16B | $489.00M | $444.00M | $251.00M | $122.00M |
| Depreciation & amortization | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $4.48B | $2.93B | $1.82B | $6.84B | $2.53B | $1.17B | $2.51B | $8.51B | $4.85B | $2.23B |
| Gross margin | 73.5% | 74.2% | 66.2% | 77.7% | 77.5% | 78.0% | 75.5% | 75.5% | 76.8% | 77.6% |
| Operating margin | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| FCF margin | 27.0% | 18.0% | 11.1% | 39.6% | 16.0% | 7.5% | 16.1% | 51.1% | 30.1% | 14.1% |
| SBC / revenue | 1.8% | 1.1% | 1.2% | 1.2% | 1.4% | 1.3% | 1.2% | 1.2% | 1.3% | 1.1% |
| Current ratio | 1.32x | 1.30x | 1.54x | 1.66x | 1.42x | 1.41x | 1.36x | 1.36x | 1.47x | 1.25x |
| Revenue YoY growth | 5.1% | 4.9% | 5.0% | 3.7% | -1.9% | -1.6% | 6.8% | 4.4% | 7.2% | 8.9% |
| Net margin | -8.0% | -26.0% | 18.1% | 33.5% | 28.0% | 32.7% | 24.0% | 19.0% | 33.9% | 30.2% |
| R&D / revenue | 58.7% | 77.3% | 23.7% | 24.5% | 25.6% | 23.3% | 29.3% | 35.2% | 21.7% | 25.3% |
| CapEx / revenue | 5.4% | 6.1% | 6.3% | 5.7% | 4.8% | 8.6% | 6.0% | 4.7% | 4.9% | 5.5% |
| Long-term debt / equity | 1.22x | Unavailable | 0.89x | 0.77x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | 13.4% | 14.2% | 11.4% | 13.9% | 10.2% | 22.7% | 9.1% | 15.9% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MRK in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-02View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.